On October 7, WUXI XDC fell 3.38% in regular trading, trading at HK$81.1 per share, with turnover of HK$3.97 million.
The decline came amid broad weakness in the life sciences tools and services sector, as peer stocks generally pulled back and weighed on WUXI XDC. In the sector, WUXI BIO fell 3.11%, GENSCRIPT BIO tumbled 14.29%, WUXI APPTEC slipped 1.74%, INSILICO dropped 8.43%, and XTALPI declined 7.22%.
WUXI XDC is an investment holding company principally engaged in providing comprehensive contract research, development, and manufacturing organization services for antibody-drug conjugates and other bioconjugates. Its services cover discovery, process development, and GMP manufacturing of bioconjugates, monoclonal antibody intermediates, and related linkers and payloads. The company primarily operates in domestic markets, North America, Europe, and other regions worldwide.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)